First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers | Zendy

James C. Gilbert | Zendy; Tia DeFeo-Fraulini | Zendy; Renta Hutabarat | Zendy; Christopher Horvath | Zendy; Patricia G. Merlino | Zendy; H. Nicholas Marsh | Zendy; Judith M. Healy | Zendy; Sleiman BouFakhreddine | Zendy; Thomas V. Holohan | Zendy; Robert G. Schaub | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

First-in-Human Evaluation of Anti–von Willebrand Factor Therapeutic Aptamer ARC1779 in Healthy Volunteers

Author(s) -

James C. Gilbert,

Tia DeFeo-Fraulini,

Renta Hutabarat,

Christopher Horvath,

Patricia G. Merlino,

H. Nicholas Marsh,

Judith M. Healy,

Sleiman BouFakhreddine,

Thomas V. Holohan,

Robert G. Schaub

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.107.724864

Subject(s) - medicine , aptamer , von willebrand factor , immunology , pharmacology , platelet , genetics , biology

ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research